

## **AHI Updated Appendix 3Bs**

**Advanced Health Intelligence Ltd (ASX:AHI) (AHI or the Company)** advises that it has found it necessary to amend an Appendix 3B issued on 15 April 2024, where it was found to have incorrectly described an attaching security as an unquoted Option, when it should have read as an Ordinary Share. An amended Appendix 3B will be released today to correct this error.

The Company has also found it necessary to amend an Appendix 3B issued on 2 October 2024, where it was found that the quantity of Ordinary Shares and free attaching Options had been incorrectly stated. An amended Appendix 3B will be released today to correct this error.

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

For more information, contact:

**Scott Montgomery**  
**Chief Executive Officer**  
Advanced Health Intelligence Ltd  
E: [admin@ahi.tech](mailto:admin@ahi.tech)

**Simon Durack**  
**Company Secretary & CFO**  
Advanced Health Intelligence Ltd  
E: [admin@ahi.tech](mailto:admin@ahi.tech)

### **About Advanced Health Intelligence Ltd**

Advanced Health Intelligence (AHI) delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

- Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
- Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging is used to return vital signs and provide risk estimates for cardiovascular disease.
- On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
- Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

**Market Announcement**  
**17 October 2024**



For more information, please visit: [www.ahi.tech](http://www.ahi.tech)